Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission

　　1.Why response is not judged in a few days

　　Bosutinib inhibits BCR-ABL1 and Src-family kinases for Philadelphia chromosome-positive chronic myeloid leukemia(CML).Inhibition begins after dosing,but CML is indolent;subjective improvement alone is not proof of control.Efficacy is assessed by complete blood count,quantitative BCR-ABL1 in peripheral blood,bone marrow cytogenetics or FISH,not by how quickly symptoms change.

　　2.Stage-by-stage monitoring

　　First weeks:some patients achieve hematologic normalization of WBC/platelets,but this is only the superficial layer of response.

　　Around 3 months:quantitative BCR-ABL1 IS is used as an early benchmark.Suboptimal decline should trigger review of adherence,drug interactions,and toxicity before any conclusion.

　　Around 6 months:cytogenetic or molecular reassessment;a continuing downward trend supports the current regimen.

　　12 months and later:evaluate major molecular response(MMR,BCR-ABL IS≤0.1%)and deeper targets.In newly diagnosed chronic-phase studies,median time to MMR varies by population and regimen;"several months to about one year"is a reasonable general frame,not a threshold for declaring failure if earlier results are improving.

　　Maintenance:after stable MMR,molecular testing is often repeated every 3–6 months;rising transcripts or loss of response require repeat testing and ABL kinase-domain sequencing.

　　3.Dosing and response

　　Adults with newly diagnosed chronic-phase Ph+CML often start 400mg once daily with food;adults with prior resistance/intolerance in chronic phase,or accelerated/blast phase,often start 500mg once daily.If response is inadequate without grade≥3 toxicity,physicians may uptitrate by 100mg to a maximum 600mg once daily;hepatotoxicity,severe diarrhea,or significant myelosuppression requires hold,reduction,or discontinuation.If a dose is missed by more than 12 hours,skip it and resume the next scheduled dose.

　　4.Resistance mutations and regimen review

　　Bosutinib retains activity against many imatinib-resistance BCR-ABL variants but has weak or no reliable activity against T315I and limited activity against V299L.For persistent non-response,a rise from best-obtained BCR-ABL by about one log,or disease progression,perform ABL kinase-domain sequencing;choose another TKI,combination,or specialist pathway based on mutation,phase,and prior tolerance rather than self-escalating.

　　5.Patient execution

　　Do not stop because there is no quick symptom change,and do not increase dose only because MMR is not yet reached.Keep scheduled CBC,liver/renal tests,and BCR-ABL quantification at 3,6,and 12 months.Review strong CYP3A inhibitors/inducers,PPIs,anticoagulants,and other oncologics with a pharmacist to avoid exposure and safety problems.